FDA Approves Aimovig ™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Migraine is a Severe Neurologic Disease That Profoundly Impacts Millions of Patients in the United States
Aimovig is the First and Only FDA-Approved Treatment to Block the Calcitonin Gene-Related Peptide Receptor (CGRP-R), Which Plays an Important Role in Migraine
Aimovig was Consistently Shown to Reduce Monthly Migraine Days, Including in More Difficult-to-Treat Populations, With Many Patients Achieving at Least a 50 Percent Reduction
THOUSAND OAKS, Calif., May 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel ther...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Brain | Food and Drug Administration (FDA) | Genetics | Headache | Migraine | Neurology | Pharmaceuticals | USA Health